Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Dose Reduction in Schizophrenia (DORIS) Study: a final report

J Hirschowitz1, R Hitzemann, K Piscani

  • 1Psychiatry Service 116A, Bronx VAMC, NY 10468, USA.

Schizophrenia Research
|January 17, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal and maternal outcomes of scheduled versus unscheduled ex-utero intrapartum treatment (EXIT) procedures.

International journal of pediatric otorhinolaryngology·2026
Same author

Supervised Machine Learning to Identify Hospital Inpatients Needing a Change of Antibiotic Therapy in Real Time: Preclinical Diagnostic Evaluation and Feasibility Study.

Open forum infectious diseases·2026
Same author

Moving From 'Best Interests' to 'Will and Preference': A Study of Doctors' Level of Knowledge Relating to the Assisted Decision-Making (Capacity) Act 2015.

Irish medical journal·2022
Same author

Investigating the prevalence of low energy availability, disordered eating and eating disorders in competitive and recreational female endurance runners.

European journal of sport science·2022
Same author

Season-Long Changes in the Body Composition Profiles of Competitive Female Rugby Union Players Assessed via Dual Energy X-Ray Absorptiometry.

Research quarterly for exercise and sport·2021
Same author

Top 10 priorities for future infertility research: an international consensus development study.

Fertility and sterility·2020

Dopamine D2 receptor blockade, not haloperidol levels, improved positive psychotic symptoms in schizophrenia. Lower blockade doses showed greater efficacy, while higher blockade improved negative symptoms, suggesting tailored neuroleptic treatment strategies.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia treatment often involves dopamine D2 receptor antagonists like haloperidol.
  • Optimizing neuroleptic dosing and receptor blockade is crucial for therapeutic efficacy and minimizing side effects.

Purpose of the Study:

  • To investigate the relationship between dopamine D2 receptor blockade levels and therapeutic response in chronic schizophrenia.
  • To compare the efficacy of different blockade percentages and haloperidol concentrations on positive and negative psychotic symptoms.

Main Methods:

  • Randomized assignment of medication-free patients to 50% or 100% growth hormone (GH) response blockade, or 10 ng/ml haloperidol.
  • Randomized assignment of patients on haloperidol to placebo, 100% GH response blockade, or 10 ng/ml haloperidol.

Related Experiment Videos

  • Assessment of positive and negative psychotic symptoms over 6 weeks.

    • Main Results:

    • Significant improvement in positive symptoms was observed in 6/7 responders, primarily in the 50% and 100% blockade groups, indicating dose-dependent efficacy.
    • Negative symptoms improved in 3/4 responders, exclusively within the 100% blockade group.
    • Patients on 100% blockade achieved dose reduction and significant plasma haloperidol level decrease, unlike the placebo group which deteriorated.

    Conclusions:

    • Dopamine D2 receptor blockade, rather than absolute plasma haloperidol levels, appears to be the key determinant of therapeutic response in schizophrenia.
    • Lower blockade levels may be sufficient for positive symptom improvement, while higher levels are needed for negative symptom amelioration.
    • Findings suggest potential for dose optimization and management of neuroleptic tolerance mechanisms.